Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect of NovoCure Ltd from 31 Dec 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Summary
NovoCure Ltd quarterly and annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect in USD history and change rate from 31 Dec 2017 to 30 Sep 2025.
  • NovoCure Ltd Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the quarter ending 30 Sep 2025 was $192,505,000, a 827% increase year-over-year.
  • NovoCure Ltd Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for the twelve months ending 30 Sep 2025 was $155,439,000, a 376% increase year-over-year.
  • NovoCure Ltd annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2024 was $76,470,000, a 160% decline from 2023.
  • NovoCure Ltd annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2023 was $126,730,000.
  • NovoCure Ltd annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect for 2022 was $93,775,000, a 156% decline from 2021.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Trailing 12 Months (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Quarterly (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Quarterly Change (%)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Annual (USD)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, YoY Annual Change (%)

NovoCure Ltd Quarterly Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $155,439,000 $192,505,000 +$171,749,000 +827% 01 Jul 2025 30 Sep 2025 10-Q 30 Oct 2025 2025 Q3
Q2 2025 $16,310,000 $22,702,000 +$311,622,000 01 Apr 2025 30 Jun 2025 10-Q 24 Jul 2025 2025 Q2
Q1 2025 $327,932,000 $36,663,000 -$251,462,000 -117% 01 Jan 2025 31 Mar 2025 10-Q 24 Apr 2025 2025 Q1
Q4 2024 $76,470,000 $23,105,000 -$109,157,000 -127% 01 Oct 2024 31 Dec 2024 10-Q 30 Oct 2025 2025 Q3
Q3 2024 $32,687,000 $20,756,000 +$21,738,000 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2025 2025 Q3
Q2 2024 $10,949,000 $288,920,000 -$259,775,000 -891% 01 Apr 2024 30 Jun 2024 10-Q 24 Jul 2025 2025 Q2
Q1 2024 $270,724,000 $214,799,000 +$143,994,000 +203% 01 Jan 2024 31 Mar 2024 10-Q 24 Apr 2025 2025 Q1
Q4 2023 $126,730,000 $86,052,000 +$214,254,000 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $87,524,000 $982,000 +$122,745,000 +99% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 $210,269,000 $29,145,000 -$205,280,000 -117% 01 Apr 2023 30 Jun 2023 10-Q 25 Jul 2024 2024 Q2
Q1 2023 $4,989,000 $70,805,000 +$88,786,000 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $93,775,000 $128,202,000 +$352,881,000 +73% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $446,656,000 $123,727,000 -$453,832,000 -137% 01 Jul 2022 30 Sep 2022 10-Q 26 Oct 2023 2023 Q3
Q2 2022 $7,176,000 $176,135,000 +$141,525,000 +409% 01 Apr 2022 30 Jun 2022 10-Q 27 Jul 2023 2023 Q2
Q1 2022 $134,349,000 $17,981,000 -$97,785,000 -123% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $36,564,000 $481,083,000 -$491,875,000 -4558% 01 Oct 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
Q3 2021 $455,311,000 $330,105,000 +$292,309,000 +773% 01 Jul 2021 30 Sep 2021 10-Q 27 Oct 2022 2022 Q3
Q2 2021 $163,002,000 $34,610,000 +$19,730,000 +133% 01 Apr 2021 30 Jun 2021 10-Q 28 Jul 2022 2022 Q2
Q1 2021 $143,272,000 $79,804,000 +$76,515,000 +2326% 01 Jan 2021 31 Mar 2021 10-Q 28 Apr 2022 2022 Q1
Q4 2020 $66,757,000 $10,792,000 +$41,544,000 01 Oct 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
Q3 2020 $25,213,000 $37,796,000 +$9,811,000 +35% 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021 2021 Q3
Q2 2020 $15,402,000 $14,880,000 -$13,142,000 -47% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 $28,544,000 $3,289,000 -$8,116,000 -71% 01 Jan 2020 31 Mar 2020 10-Q 29 Apr 2021 2021 Q1
Q4 2019 $36,660,000 $30,752,000 -$48,350,000 -275% 01 Oct 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
Q3 2019 $85,010,000 $27,985,000 +$19,452,000 +228% 01 Jul 2019 30 Sep 2019 10-Q 29 Oct 2020 2020 Q3
Q2 2019 $65,558,000 $28,022,000 +$25,158,000 +878% 01 Apr 2019 30 Jun 2019 10-Q/A 02 Oct 2020 2020 Q2
Q1 2019 $40,400,000 $11,405,000 -$21,638,000 -65% 01 Jan 2019 31 Mar 2019 10-Q/A 02 Oct 2020 2020 Q1
Q4 2018 $62,038,000 $17,598,000 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $8,533,000 01 Jul 2018 30 Sep 2018 10-Q 31 Oct 2019 2019 Q3
Q2 2018 $2,864,000 01 Apr 2018 30 Jun 2018 10-Q 25 Jul 2019 2019 Q2
Q1 2018 $33,043,000 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1

NovoCure Ltd Annual Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $76,470,000 -$203,200,000 -160% 01 Jan 2024 31 Dec 2024 10-Q 30 Oct 2025 2025 Q3
2023 $126,730,000 +$220,505,000 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $93,775,000 -$57,211,000 -156% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $36,564,000 -$103,321,000 -155% 01 Jan 2021 31 Dec 2021 10-K 22 Feb 2024 2023 FY
2020 $66,757,000 +$30,097,000 +82% 01 Jan 2020 31 Dec 2020 10-K 23 Feb 2023 2022 FY
2019 $36,660,000 -$25,378,000 -41% 01 Jan 2019 31 Dec 2019 10-K 24 Feb 2022 2021 FY
2018 $62,038,000 +$81,368,000 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $19,330,000 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.